using pain phenotyping to reduce opioid exposure
play

Using Pain Phenotyping To Reduce Opioid Exposure Paul Coelho, MD - PowerPoint PPT Presentation

Using Pain Phenotyping To Reduce Opioid Exposure Paul Coelho, MD Josh Steenstra, MBA Disclosures Dr. Coelho & Mr. Steenstra have no relevant disclosures. We will not be discussing any off-label uses of medications or devices. Table of


  1. Using Pain Phenotyping To Reduce Opioid Exposure Paul Coelho, MD Josh Steenstra, MBA

  2. Disclosures Dr. Coelho & Mr. Steenstra have no relevant disclosures. We will not be discussing any off-label uses of medications or devices.

  3. Table of contents: Epidemiology of the opioid epidemic • Oregon opioid prescribing • • Pain phenotyping Salem Clinic 18mo data • • Sample Case Evidence-Based Treatments • • ICD10 Codes

  4. Epidemiology of the Opioid Epidemic

  5. US Overdose Deaths 1980-2017 Peak Incidence Ages 45-54 Peak Incidence of Prescription ODD Age 45-54* 67K 50000 37500 25000 12500 6K 0 1980 2017

  6. OD’s Vs Guns Vs MVA’s

  7. US OD Hospitalizations By Race https://www.cdc.gov/nchs/products/databriefs/db294.htm

  8. International Opioid Prescribing 2012-2014 https://www.ncbi.nlm.nih.gov/pubmed/28792397

  9. International Oxycodone Prescribing

  10. International Prevalence of Chronic Pain https://www.ncbi.nlm.nih.gov/pubmed/28792397

  11. Oregon & Prescribed Opioids

  12. 2011 Oregon Opioid Prescribing for SSD Recipients < 65yrs https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4151179/

  13. Opioid Prescribing for Fibromyalgia 2007-09 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4346177/

  14. Pain Phenotyping to Reduce Opioid Exposure

  15. 2018 Model of MSK Pain Nociceptive Neuropathic Nociplastic Primarily due to Damage or entrapment of Primarily due to a inflammation or tissue peripheral nerves. central disturbance in damage in the periphery pain processing. NSAID/Opioid Responsive Responds to both Tricyclic neuro-active peripheral and central compounds. Opioid pharmacotherapy. unresponsive. Responds to procedures. Does not respond to Does not respond to procedures. procedures. Behavioral factors minor. Behavioral factors minor. Behavioral Factors Prominent. Examples: Osteoarthritis, Examples: Diabetic Examples: FMS, cLBP, Rheumatoid arthritis, peripheral neuropathy, cHA, IBS. cancer pain. post-herpetic neuralgia. https://www.ncbi.nlm.nih.gov/pubmed/26266995

  16. Identifying the Nociplastic- AKA “Central” – Pain Phenotype 1 . Pain in many body regions. 2. Higher current and lifetime history of chronic pain in several body regions. 3. Multiple somatic symptoms (e.g., fatigue, memory difficulties, sleep problems, mood disturbance) 4. Negative Affect, dispositional pessimism, pain catastrophizing. 5. More sensitive to other sensory stimuli (e.g., bright light, loud noises, odors, other sensations in internal organs) 6. 1.5 to 2x more common in women. 7. Strong family history of chronic pain. 8. High self-reported pain & distress (VAS/NPS/PSD/PCS) 9. Pain triggered or exacerbated by stressors. 10. Peak prevalence of FMS age 30-59 (working-age).* 11. Essentially normal physical examination +/- diffuse tenderness. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1829161/

  17. Pain Catastrophizing Scale Abnormal if > 20 http://sullivan-painresearch.mcgill.ca/pdf/pcs/PCSManual_English.pdf

  18. 2016 Fibromyalgia Survey Questionnaire FMS + if Total Score > 13 https://www.ncbi.nlm.nih.gov/pubmed/27916278

  19. Salem Clinic Data

  20. Demographics: Sex 978 Referrals 615 (63%) women 363 (37%) men

  21. Demographics: Age 978 Referrals 539 (55%) 45-64 250 (26%) 18-44 233 (24%) > 65

  22. Demographics: Payer

  23. 18mo Look Back At The Nociplastic Phenotype 987 Referrals 682 (69%) FMS+ PCS + 553 (56%) FMS+ 481 (48%) PCS+ 305 (31%) FMS- PCS-

  24. 18mo Look Back Opioid Exposure 977 Referrals 671 (66%) FMS+ or PCS + 422 of 671 (63%) Rx’d a schedule II

  25. 18mo Look Back @ PCS & Opioid Use Disorder (F11.2) 131 Dx of OUD 91 (69%) PCS > 20 40 (31%) PCS < 20 OR = 2.5, CI[1.6-3.9] p < 0.0001 https://www.medcalc.org/calc/odds_ratio.php

  26. OR High Utilizer ED Visits 6 of top 10 Visits for Pain http://www.orhealthleadershipcouncil.org/wp-content/uploads/2017/09/EDIE-Evaluation-Report-Final-8-21-17-v.1.pdf

  27. 18mo Look Back ED Visits 472 ED Visits 397 (84%) FMS+ PCS+ 75 (16%) FMS - or PCS – OR = 2.4, CI [1.8-3.2] p < 0.0001 https://www.medcalc.org/calc/odds_ratio.php

  28. 18mo Look Back HA & Migraine 310 HA or Migraineur 253 (80%) FMS+ PCS+ 62 (20%) FMS - or PCS – OR = 1.86, CI [1.4-2.5] p = 0.0001 https://www.medcalc.org/calc/odds_ratio.php

  29. 18mo Look Back > 4 Opioid Prescribers (Z72.89) 76 Occurrences of doctor shopping 63 (83%) FMS+ PCS+ 13 (17%) FMS - or PCS – OR = 2.2,CI [1.19-4.1] p = 0.011 https://www.medcalc.org/calc/odds_ratio.php

  30. 18mo Look Back Cervical & Lumbar MRIs 136 Cervical & Lumbar MRIs 107 (79%) FMS+ PCS+ 29 (21%) FMS - or PCS – OR 1.7, CI[1.1-2.6] p = 0.0018 https://www.medcalc.org/calc/odds_ratio.php

  31. Sample Case

  32. Joyce Joyce is a 45y/o woman who recently moved from CA to Jackson, County to retire. Her past medical history is significant for a work related back injury for which she was medically retired. She now receives SSD and seeks to establish care with you for primary care needs as well as pain management. Her medication regimen consists of Lisinopril for HTN. She is requesting “Percocet” for pain.

  33. Joyce 10 >13 = FMS >13 = FMS 17 7

  34. Joyce 4 4 3 4 3 4 4 3 4 4 3 4 4 48/52 >30 Abnl

  35. Evidence-Based Treatments

  36. Evidence-Based Treatments for FMS Treatment Evidence Level Patient Education 1A Graded Exercise 1A CBT 1A Tricyclics 1A SNRI’s 1A Gabapentenoids 1A NSAIDS 5D Opioids 5D https://www.ncbi.nlm.nih.gov/pubmed/28077978

  37. Evidence-Based Treatments for Pain Catastrophizising

  38. Supporting ICD-10/DSM 5 Codes

  39. ICD-10 & DSM 5 Codes Diagnosis ICD-10/DSM 5 Fibromyalgia M79.7 Pain Catastrophizing F45.1

  40. Thank you! paul.coelho@salemhealth.org joshua.steenstra@salemhealth.org

Recommend


More recommend